Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
published in: The Lancet: Diabetes & Endocrinology
date of publication: 2013-09-23
language: English
main subject: phase II clinical trial, placebo, type-1 diabetes
Cites articles 28
- 2004-02-01
Date
Title
Article - wd:Q37642554